Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PAVmed Inc. (PAVM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed, commercial-stage medical technology company. Through these documents, investors can review how PAVmed reports its operations in the medical device, diagnostics, and digital health sectors, along with detailed financial information and corporate actions.
Current reports on Form 8-K include items such as press releases announcing quarterly financial results and business updates. For example, PAVmed has filed an 8-K to furnish a press release covering financial results for the quarter ended September 30, 2025 and a related business update. These filings give context on revenue, operating expenses, non-GAAP measures such as EBITDA and adjusted loss, and commentary on the performance of subsidiaries like Lucid Diagnostics Inc. and Veris Health Inc.
Proxy materials such as the definitive proxy statement on Schedule 14A provide insight into corporate governance and stockholder proposals. PAVmed’s definitive proxy statement for a special meeting of stockholders describes proposals to approve a reverse stock split within a specified ratio range and a reduction in authorized common stock, along with the reasons for these actions, including efforts to meet Nasdaq’s minimum bid price requirement.
On this page, users can also monitor periodic reports such as Forms 10-Q and 10-K (when available), which contain comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures. These filings are important for understanding PAVmed’s financial condition, capital structure, and its activities in medical technology development, commercialization, and digital health.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping readers quickly identify information on topics such as quarterly performance, non-GAAP reconciliations, reverse stock split mechanics, and subsidiary operations. The platform also surfaces real-time updates from EDGAR, so new PAVM filings appear promptly as they are submitted.
PAVmed Inc. registered 9,230,786 shares of common stock for resale by selling stockholders, consisting of 4,615,393 shares issued upon conversion of Series D preferred and 4,615,393 shares issuable upon exercise of related warrants. The company is not selling shares here and will not receive proceeds from resales; it may receive up to $30,000,000 to the extent the Warrants are exercised. The registration covers resale by the listed selling stockholders and permits the shares to be sold on exchanges, OTC or by negotiated transactions, at the selling holders' discretion.
PAVmed Inc. files a registration statement to permit resale of 9,230,786 shares of common stock by selling stockholders. The shares consist of 4,615,393 shares issued upon conversion of Series D preferred stock and 4,615,393 shares issuable upon exercise of warrants tied to that private placement. The company is not selling shares here and will receive proceeds only if the warrants are exercised — up to $30,000,000 — with proceeds intended for working capital and general corporate purposes. The prospectus discloses the Series D conversion price of $6.50 per share, a warrant exercise mechanism that may deliver common shares in lieu of preferred, and a callable feature tied to MolDx publication of a draft Medicare local coverage determination.
PAVmed Inc. Schedule 13G/A reports that Tasso Partners, LLC beneficially owns 912,996 shares (14.3%) and that Dana Carrera beneficially owns 974,246 shares (15.3%). The filing ties the ownership percentages to 6,383,089 shares outstanding as of March 27, 2026 and discloses related convertible warrants and managerial control relationships.
Lee Victoria Tou-ho reported acquisition or exercise transactions in this Form 4 filing.
PAVmed Inc. reported that Chief Medical Officer Lee Victoria Tou-ho received a grant of 70,000 shares of common stock as an equity award. The restricted stock was granted at $0.00 per share and increases her direct holdings to 71,666 shares.
The award consists of restricted stock under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed, tying the grant to long-term employment and performance.
PAVmed Inc. filed an initial insider report for Chief Medical Officer Lee Victoria Tou-ho, showing ownership of 1,666 shares of Common Stock as restricted stock granted under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
These restricted shares have a single vesting date of May 20, 2028 and are subject to forfeiture if the required service period is not completed, meaning the CMO must remain in service through that date to fully retain the award.
Scopia Holdings LLC and Matthew Sirovich reported beneficial ownership stakes in PAVmed Inc. Scopia Holdings LLC beneficially owns 630,118 shares of Common Stock (CUSIP 70387R502), representing 9.87%. Mr. Matthew Sirovich is reported as beneficially owning 637,670 shares, representing 9.99%, which reflects his control over the Scopia holdings plus 7,552 additional shares. The reporting address is c/o Scopia Capital Management LP, and the signature date provided is 04/13/2026.
PAVmed Inc. Chairman and CEO Lishan Aklog, M.D. filed a Schedule 13D reporting beneficial ownership of 369,068 shares of PAVmed common stock, representing 5.1% of the 7,272,739 shares outstanding as of April 2, 2026. The issuer granted him 350,000 shares of restricted common stock under its Seventh Amended and Restated Long-Term Incentive Equity Plan in consideration of services as Chairman and CEO. These restricted shares, along with existing holdings, options and small indirect interests through entities and family members, make up his reported beneficial ownership. The filing states the shares are held for investment purposes and that, apart from routine investment activity consistent with his roles, he has no current plans for major corporate changes.
PAVmed Inc. reports Schedule 13G ownership disclosures by David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust. The filing states the Trust beneficially owns 461,539 shares (7.2%) and Mr. Nagelberg beneficially owns 546,964 shares (8.6%), based on 6,383,089 shares outstanding as of March 27, 2026. The Trust holdings are controlled by Mr. Nagelberg; sole voting and dispositive power figures match the share counts. A Joint Filing Agreement is included as Exhibit 99.1.
PAVmed Inc. Schedule 13G filed by Scott V. Dols reports beneficial ownership of 346,155 shares of Common Stock, representing 5.4% of the class. The percent is calculated using 6,383,089 shares outstanding as of March 27, 2026 per the company annual report.
Tasso Partners, LLC filed an initial ownership report as a more than ten percent owner of PAVmed Inc.. The filing shows direct ownership of 912,996 shares of Common Stock. It also reports a Warrant to purchase up to 5,365 shares of Series D Preferred Stock at $1,000 per share, expiring on February 3, 2031. Each Series D Preferred share has a stated value of $1,000 and is convertible into Common Stock at a $6.50 per share conversion price, for an aggregate of up to 825,385 shares of Common Stock. The issuer may choose, upon exercise of the Warrant, to issue those Common Stock shares directly instead of issuing the preferred shares first.